AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19832114 — intervention group
Group type: COMPARATOR
Intervention: HAART-eligible/untreated (CD4 <250 cells/microL, no HAART received)
Number of subjects: 2318
Study 19832114 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART-eligible/treated (CD4 <250 cells/microL, HAART received)
Number of subjects: 2318
Study 19832114 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART-ineligible (CD4 ≥250 cells/microL)
Number of subjects: 2318
Study 19832114 — intervention group
Group type: COMPARATOR
Intervention: HAART-eligible/treated vs HAART-eligible/untreated
Number of subjects: 2318
Study 17576783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg daily)
Number of subjects: 498
Study 17576783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 15465746 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid (S)
Number of subjects: 16
Study 15465746 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (P)
Number of subjects: 16
Study 15465746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid
Number of subjects: 16
Study 15465746 — intervention group
Group type: EXPERIMENTAL
Intervention: C18:1 trans (T)
Number of subjects: 16
Study 15465746 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 16
Study 11459728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium enhanced 3D MR angiography (MRA)
Number of subjects: 41
Study 9702848 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (bumetanide 1 mg daily and furosemide 40 mg daily)
Number of subjects: 27
Study 9702848 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg daily
Number of subjects: 27
Study 9702848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9606629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone (M) mornings/dithranol (D) evenings (M/D)
Number of subjects: 30
Study 9606629 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (C) mornings/dithranol (D) evenings (C/D)
Number of subjects: 30
Study 9606629 — intervention group
Group type: COMPARATOR
Intervention: Dithranol (D) twice a day (D/D)
Number of subjects: 30
Study 9606629 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 4 weeks
Number of subjects: 30
Study 1890447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohmeda 2120 monitor
Number of subjects: 16
Study 1890447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sys Stat mode
Number of subjects: 16
Study 1890447 — intervention group
Group type: COMPARATOR
Intervention: Arterial cannula
Number of subjects: 16
Study 7121527 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 J shocks
Number of subjects: 249
Study 7121527 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 J shocks
Number of subjects: 249
Study 7121527 — intervention group
Group type: COMPARATOR
Intervention: Survivors
Number of subjects: 249
Study 30633218 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (2g on both shoulders)
Number of subjects: 75
Study 30633218 — intervention group
Group type: COMPARATOR
Intervention: Trigger point injection (2mL of 0.2% ropivacaine)
Number of subjects: 75
Study 30633218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study 29507777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 2584
Study 27089170 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6
Number of subjects: 0
Study 27089170 — intervention group
Group type: COMPARATOR
Intervention: placebo-R-CHOP21 × 6
Number of subjects: 0
Study 25006768 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket grafting and polytetrafluoroethylene (PTFE) barrier
Number of subjects: 20
Study 25006768 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket grafting, buccal overbuilding, and PTFE barrier
Number of subjects: 20
Study 25006768 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket grafting, collagen barrier, and PTFE barrier
Number of subjects: 20
Study 25006768 — intervention group
Group type: COMPARATOR
Intervention: Collagen plug (control)
Number of subjects: 20
Study 25006768 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 22443165 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation from FAP donor (Group 1)
Number of subjects: 44
Study 22443165 — intervention group
Group type: COMPARATOR
Intervention: Liver transplantation from non-FAP cadaveric donor (Group 2)
Number of subjects: 44
Study 20398311 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN 40 ml enema (10E8 EcN/ml)
Number of subjects: 90
Study 20398311 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN 20 ml enema (10E8 EcN/ml)
Number of subjects: 90
Study 20398311 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN 10 ml enema (10E8 EcN/ml)
Number of subjects: 90
Study 20398311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18507881 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with vitamins/minerals (Pharmaton Kiddi) for 12 weeks
Number of subjects: 81
Study 15969833 — intervention group
Group type: EXPERIMENTAL
Intervention: RR participants (remember both lists)
Number of subjects: 0
Study 15969833 — intervention group
Group type: COMPARATOR
Intervention: FR participants (forget the first list, remember the second list)
Number of subjects: 0
Study 15969833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RR and FR participants)
Number of subjects: 0
Study 14581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin (5 mg/kg every 8 hours)
Number of subjects: 24
Study 14581796 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose placebo
Number of subjects: 24
Study 14581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin
Number of subjects: 24
Study 10654172 — intervention group
Group type: EXPERIMENTAL
Intervention: Early grid laser treatment
Number of subjects: 99
Study 10654172 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed grid laser treatment
Number of subjects: 99
Study 10654172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 9115016 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermatching using 3 controls per case
Number of subjects: 100
Study 9115016 — intervention group
Group type: COMPARATOR
Intervention: Random sampling using 10 controls
Number of subjects: 100
Study 9115016 — intervention group
Group type: COMPARATOR
Intervention: Random sampling using 3 controls per case
Number of subjects: 100
Study 8241496 — intervention group
Group type: EXPERIMENTAL
Intervention: All transretinoic acid (ATRA) combined with daunorubicin‐Ara C chemotherapy
Number of subjects: 101
Study 8241496 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin‐Ara C chemotherapy
Number of subjects: 101
Study 2883819 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 8
Study 2883819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 8
Study 2883819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31035469 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquilea Colesterol® (nutraceutical combination)
Number of subjects: 40
Study 30284506 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of contralesional M1
Number of subjects: 45
Study 30284506 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint therapy
Number of subjects: 45
Study 30284506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rTMS and constraint therapy
Number of subjects: 45
Study 30284506 — intervention group
Group type: COMPARATOR
Intervention: Neither rTMS nor constraint therapy (control group)
Number of subjects: 45
Study 26706610 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning loop ileostomy
Number of subjects: 166
Study 26706610 — intervention group
Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 166
Study 25113835 — intervention group
Group type: EXPERIMENTAL
Intervention: SANGUINATE 80 mg/kg
Number of subjects: 24
Study 25113835 — intervention group
Group type: EXPERIMENTAL
Intervention: SANGUINATE 120 mg/kg
Number of subjects: 24
Study 25113835 — intervention group
Group type: EXPERIMENTAL
Intervention: SANGUINATE 160 mg/kg
Number of subjects: 24
Study 25113835 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 24
Study 22674050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol AML02
Number of subjects: 351
Study 22674050 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 10 to 21 years
Number of subjects: 351
Study 19462324 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA chocolate (10 g with 28 mg GABA)
Number of subjects: 0
Study 17804831 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support (six sessions of individual and family counseling, support group participation, continuous availability of ad-hoc telephone counseling)
Number of subjects: 406
Study 17804831 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study 15732861 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 35
Study 15732861 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 35
Study 11380066 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 29
Study 11380066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8355039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE2) 50 micrograms administered 24 hours before chemotherapy (FAC)
Number of subjects: 154
Study 8355039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) administered 24 hours before chemotherapy (FAC)
Number of subjects: 154
Study 3320135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudocrem
Number of subjects: 0
Study 3320135 — intervention group
Group type: COMPARATOR
Intervention: Zinc cream BP
Number of subjects: 0
Study 29557719 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies (no specified limits on shift length or mandatory time off between shifts)
Number of subjects: 63
Study 29557719 — intervention group
Group type: COMPARATOR
Intervention: Standard duty-hour policies (2011 ACGME guidelines)
Number of subjects: 63
Study 28851420 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (verum acupuncture)
Number of subjects: 74
Study 28851420 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 74
Study 23486907 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (50 mg/day) plus placebo
Number of subjects: 60
Study 23486907 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (50 mg/day) plus hydrochlorothiazide (25 mg/day)
Number of subjects: 60
Study 23486907 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day) plus placebo
Number of subjects: 60
Study 23883613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle Navigator continuous subcutaneous glucose values, n = 12)
Number of subjects: 24
Study 23883613 — intervention group
Group type: COMPARATOR
Intervention: Local protocol with intravenous sliding-scale insulin (n = 12)
Number of subjects: 24
Study 23883613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop therapy
Number of subjects: 24
Study 23883613 — intervention group
Group type: COMPARATOR
Intervention: Local protocol with intravenous sliding-scale insulin
Number of subjects: 24
Study 21602550 — intervention group
Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 22
Study 21602550 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 22
Study 18648850 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 150
Study 18648850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure vessel sealing system (LI)
Number of subjects: 150
Study 18648850 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 150
Study 17323835 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 17323835 — intervention group
Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0
Study 12761258 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 23)
Number of subjects: 44
Study 12761258 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 44
Study 10998076 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (GHRT) for 18 months
Number of subjects: 8
Study 10998076 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese subjects matched for age, sex, and BMI)
Number of subjects: 8
Study 9068509 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 60
Study 9068509 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg/day)
Number of subjects: 60
Study 9068509 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 60
Study 8409041 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG), n = 64
Number of subjects: 127
Study 8409041 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty (PTCA), n = 63
Number of subjects: 127
Study 2821056 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha hANP (0.5 microgram/min for 180 min)
Number of subjects: 6
Study 2821056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29465055 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 50
Study 29465055 — intervention group
Group type: COMPARATOR
Intervention: Control (empty socket)
Number of subjects: 50
Study 28577673 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0
Study 28577673 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care plus microfinance groups only
Number of subjects: 0
Study 28577673 — intervention group
Group type: COMPARATOR
Intervention: Group medical visits only
Number of subjects: 0
Study 28577673 — intervention group
Group type: COMPARATOR
Intervention: Group medical visits integrated into microfinance groups
Number of subjects: 0
Study 25709689 — intervention group
Group type: EXPERIMENTAL
Intervention: Role play education
Number of subjects: 67
Study 25709689 — intervention group
Group type: COMPARATOR
Intervention: Lecture group (Control)
Number of subjects: 67
Study 23470329 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Reduce Your Use program)
Number of subjects: 225
Study 23470329 — intervention group
Group type: COMPARATOR
Intervention: Control condition (6 modules of web-based educational information on cannabis)
Number of subjects: 225
Study 21146883 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 208
Study 19531812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001
Study 19531812 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001
Study 17284911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gums containing calcium (dicalcium phosphate, calcium gluconate, calcium lactate)
Number of subjects: 15
Study 17284911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing casein phosphopeptide-amorphous calcium phosphate nanocomplexes
Number of subjects: 15
Study 17284911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 15
Study 14967716 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 496
Study 14967716 — intervention group
Group type: COMPARATOR
Intervention: UFH+phenprocoumon
Number of subjects: 496
Study 11328912 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13
Study 11328912 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 13
Study 9220178 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina pectoris during the first month following discharge
Number of subjects: 803
Study 9220178 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina pectoris and heart failure
Number of subjects: 803
Study 9220178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 803
Study 8381847 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 gm/day of an 85% n-3 fatty acid concentrate for 6 weeks
Number of subjects: 14
Study 8381847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14
Study 3546466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg metaproterenol aerosol solution
Number of subjects: 100
Study 3546466 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metaproterenol aerosol solution
Number of subjects: 100
Study 3546466 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg metaproterenol aerosol solution
Number of subjects: 100
Study 3546466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg metaproterenol aerosol solution (repeated)
Number of subjects: 100
Study 3546466 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 31891539 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGHCAL diet (hypercaloric +50% caloric intake, high-saturated fat 11% energy, simple carbohydrates 54% energy)
Number of subjects: 13
Study 31891539 — intervention group
Group type: COMPARATOR
Intervention: ISOCAL diet (isocaloric, moderate saturated fat 8% energy, carbohydrates 50% energy)
Number of subjects: 13
Study 28946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training program
Number of subjects: 22
Study 28946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) training program
Number of subjects: 22
Study 27349618 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 276
Study 27349618 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (no sealant)
Number of subjects: 276
Study 27349618 — intervention group
Group type: EXPERIMENTAL
Intervention: High individual caries risk (ICR) children with carious lesions ICDAS 3-6
Number of subjects: 276
Study 27349618 — intervention group
Group type: EXPERIMENTAL
Intervention: SBDS program effectiveness based on carious lesions ICDAS 3-6
Number of subjects: 276
Study 27349618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant retention
Number of subjects: 276
Study 25128931 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (5 μg/min) without alpha-adrenergic blockade
Number of subjects: 21
Study 25128931 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (5 μg/min) with phentolamine-induced non-selective blockade
Number of subjects: 21
Study 25128931 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 21
Study 23715032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg)
Number of subjects: 20
Study 23715032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20942650 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 1771
Study 20942650 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 1771
Study 20942650 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine (ZDV) plus didanosine (ddI)
Number of subjects: 1771
Study 20942650 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine (d4T) plus lamivudine (3TC)
Number of subjects: 1771
Study 20942650 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 1771
Study 20942650 — intervention group
Group type: COMPARATOR
Intervention: ZDV+ddI
Number of subjects: 1771
Study 19020163 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 1.5% mepivacaine
Number of subjects: 90
Study 19020163 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 1% mepivacaine
Number of subjects: 90
Study 17121036 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingui Shenqi Pill plus prednisone
Number of subjects: 30
Study 17121036 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 30
Study 12936972 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once daily for 3 days (AZM-3)
Number of subjects: 936
Study 12936972 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once daily for 6 days (AZM-6)
Number of subjects: 936
Study 12936972 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (AMC) 500-125 mg three times daily for 10 days
Number of subjects: 936
Study 10506596 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 (375 microg/m(2) subcutaneously twice a day)
Number of subjects: 71
Study 10506596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 8691829 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with audience laughter present
Number of subjects: 40
Study 8691829 — intervention group
Group type: COMPARATOR
Intervention: Control condition with laughter absent
Number of subjects: 40
Study 8691829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 40
Study 1996435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg administered sublingually
Number of subjects: 0
Study 1996435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6436526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 9 g of phospholipids (PL) per day for 7 days.
Number of subjects: 12
Study 6436526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 12 g of phospholipids (PL) per day for 7 days.
Number of subjects: 12
Study 6436526 — intervention group
Group type: COMPARATOR
Intervention: Glucose administered alone as the sole source of nonprotein energy (glucose period).
Number of subjects: 12